{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T13:49:55Z","timestamp":1793368195582,"version":"4.5.0"},"reference-count":129,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T00:00:00Z","timestamp":1738281600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Intrahepatic cholangiocarcinoma is an aggressive malignancy with rising incidence and poor outcomes. This review examines recent advancements in locoregional therapies for unresectable intrahepatic cholangiocarcinoma, focusing on external beam radiotherapy, transarterial radioembolization (TARE), hepatic artery infusion pump (HAIP) chemotherapy, and liver transplantation. Stereotactic body radiation therapy and proton beam therapy have shown promise in achieving local control and improving survival. TARE, with personalized dosimetry, has demonstrated encouraging results in select patient populations. HAIP chemotherapy, primarily studied using floxuridine, has yielded impressive survival outcomes in phase II trials. Liver transplantation, once contraindicated, is now being reconsidered for carefully selected patients with localized disease. While these locoregional approaches show potential, randomized controlled trials comparing them to standard systemic therapy are lacking. Patient selection remains crucial, with factors such as liver function, tumor burden, and molecular profile influencing treatment decisions. Ongoing research aims to optimize treatment sequencing, explore combination strategies with systemic therapies, and refine phenotype identification and patient selection criteria. As the landscape of intrahepatic cholangiocarcinoma management evolves, a multidisciplinary approach is essential to tailor treatment strategies and improve outcomes for patients with this challenging disease.<\/jats:p>","DOI":"10.3390\/curroncol32020082","type":"journal-article","created":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T06:42:36Z","timestamp":1738305756000},"page":"82","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Advancements in Locoregional Therapies for Unresectable Intrahepatic Cholangiocarcinoma"],"prefix":"10.3390","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-6291-846X","authenticated-orcid":false,"given":"Conor D. J.","family":"O\u2019Donnell","sequence":"first","affiliation":[{"name":"Department of Medicine, Division of Hematology-Oncology, Mayo Clinic Florida, Jacksonville, FL 32224, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umair","family":"Majeed","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Hematology-Oncology, Mayo Clinic Florida, Jacksonville, FL 32224, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-4204-5226","authenticated-orcid":false,"given":"Michael S.","family":"Rutenberg","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Mayo Clinic Florida, Jacksonville, FL 32224, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7725-703X","authenticated-orcid":false,"given":"Kristopher P.","family":"Croome","sequence":"additional","affiliation":[{"name":"Department of Transplantation, Mayo Clinic Florida, Jacksonville, FL 32224, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine E.","family":"Poruk","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, Mayo Clinic Florida, Jacksonville, FL 32224, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beau","family":"Toskich","sequence":"additional","affiliation":[{"name":"Department of Interventional Radiology, Mayo Clinic Florida, Jacksonville, FL 32224, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7844-5833","authenticated-orcid":false,"given":"Zhaohui","family":"Jin","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,1,31]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"229","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.ejca.2021.11.023","article-title":"Global, regional and national burden of primary liver cancer by subtype","volume":"161","author":"Rumgay","year":"2022","journal-title":"Eur. J. Cancer"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Qurashi, M., Vithayathil, M., and Khan, S.A. (2023). Epidemiology of cholangiocarcinoma. Eur. J. Surg. Oncol., in press.","DOI":"10.1016\/j.ejso.2023.107064"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1016\/j.jhep.2022.07.022","article-title":"Current epidemiology of cholangiocarcinoma in Western countries","volume":"77","author":"Vithayathil","year":"2022","journal-title":"J. Hepatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e583","DOI":"10.1016\/S2468-2667(24)00156-7","article-title":"Differences in cancer rates among adults born between 1920 and 1990 in the USA: An analysis of population-based cancer registry data","volume":"9","author":"Sung","year":"2024","journal-title":"Lancet Public Health"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"223","DOI":"10.2217\/hep-2016-0009","article-title":"Monitoring outcomes in intrahepatic cholangiocarcinoma patients following hepatic resection","volume":"3","author":"Pandey","year":"2016","journal-title":"Hepat. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/j.hpb.2023.06.019","article-title":"Nationwide treatment and outcomes of intrahepatic cholangiocarcinoma","volume":"25","author":"Olthof","year":"2023","journal-title":"HPB"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1097\/SLA.0b013e318176c4d3","article-title":"Intrahepatic cholangiocarcinoma: Rising frequency, improved survival, and determinants of outcome after resection","volume":"248","author":"Endo","year":"2008","journal-title":"Ann. Surg."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"7195373","DOI":"10.1155\/2020\/7195373","article-title":"Distant Metastases in Patients with Intrahepatic Cholangiocarcinoma: Does Location Matter? A Retrospective Analysis of 370 Patients","volume":"2020","author":"Hahn","year":"2020","journal-title":"J. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2787","DOI":"10.1245\/s10434-008-0081-1","article-title":"Influence of hepatic resection margin on recurrence and survival in intrahepatic cholangiocarcinoma","volume":"15","author":"Tamandl","year":"2008","journal-title":"Ann. Surg. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1200\/JCO.21.02568","article-title":"Long-Term Outcomes and Exploratory Analyses of the Randomized Phase III BILCAP Study","volume":"40","author":"Bridgewater","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/S1470-2045(18)30915-X","article-title":"Capecitabine compared with observation in resected biliary tract cancer (BILCAP): A randomised, controlled, multicentre, phase 3 study","volume":"20","author":"Primrose","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Sharib, J., Rhodin, K.E., Liu, A., McIntyre, S., Bartholomew, A., Masoud, S., DeLaura, I., Kemeny, N.E., Cercek, A., and Harding, J.J. (2025). Adjuvant Cytotoxic Chemotherapy may not be Associated with a Survival Advantage for Resected Intrahepatic Cholangiocarcinoma. Ann. Surg. Oncol.","DOI":"10.1245\/s10434-024-16799-0"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1001\/jama.2012.7352","article-title":"Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: The ESPAC-3 periampullary cancer randomized trial","volume":"308","author":"Neoptolemos","year":"2012","journal-title":"JAMA"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1002\/bjs.10776","article-title":"Randomized clinical trial of adjuvant gemcitabine chemotherapy versus observation in resected bile duct cancer","volume":"105","author":"Ebata","year":"2018","journal-title":"Br. J. Surg."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1200\/JCO.18.00050","article-title":"Gemcitabine and Oxaliplatin Chemotherapy or Surveillance in Resected Biliary Tract Cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): A Randomized Phase III Study","volume":"37","author":"Edeline","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Stein, A., Arnold, D., Bridgewater, J., Goldstein, D., Jensen, L.H., Klumpen, H.J., Lohse, A.W., Nashan, B., Primrose, J., and Schrum, S. (2015). Adjuvant chemotherapy with gemcitabine and cisplatin compared to observation after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA-1 trial)\u2014A randomized, multidisciplinary, multinational phase III trial. BMC Cancer, 15.","DOI":"10.1186\/s12885-015-1498-0"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"4020","DOI":"10.1245\/s10434-015-4472-9","article-title":"The Impact of Surgical Margin Status on Long-Term Outcome After Resection for Intrahepatic Cholangiocarcinoma","volume":"22","author":"Spolverato","year":"2015","journal-title":"Ann. Surg. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"6495","DOI":"10.1245\/s10434-024-15582-5","article-title":"Comparing Survival of Perihilar Cholangiocarcinoma After R1 Resection Versus Palliative Chemotherapy for Unresected Localized Disease","volume":"31","author":"Buettner","year":"2024","journal-title":"Ann. Surg. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1097\/MEG.0000000000002761","article-title":"An assessment of risk factors for recurrence and survival for patients undergoing liver resection for intrahepatic cholangiocarcinoma","volume":"36","author":"Ozturk","year":"2024","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"751","DOI":"10.21037\/jgo-20-507","article-title":"The use of neoadjuvant lobar radioembolization prior to major hepatic resection for malignancy results in a low rate of post hepatectomy liver failure","volume":"12","author":"Ahmed","year":"2021","journal-title":"J. Gastrointest. Oncol."},{"key":"ref_22","unstructured":"Yeo, C.J. (2019). Chapter 117\u2014Surgical Treatment of Primary Sclerosing Cholangitis. Shackelford\u2019s Surgery of the Alimentary Tract, 2 Volume Set, Elsevier. [8th ed.]."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s13304-015-0330-3","article-title":"Intrahepatic chemotherapy for unresectable cholangiocarcinoma: Review of literature and personal experience","volume":"67","author":"Massani","year":"2015","journal-title":"Updates Surg."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.21037\/jgo.2018.07.09","article-title":"A SEER-based multi-ethnic picture of advanced intrahepatic cholangiocarcinoma in the United States pre- and post-the advent of gemcitabine\/cisplatin","volume":"9","author":"Mody","year":"2018","journal-title":"J. Gastrointest. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","article-title":"Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer","volume":"362","author":"Valle","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_26","first-page":"200","article-title":"Advanced Intrahepatic Cholangiocarcinoma: Post Hoc Analysis of the ABC-01, -02, and -03 Clinical Trials","volume":"112","author":"Lamarca","year":"2020","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1080\/0284186X.2017.1418532","article-title":"Translating the ABC-02 trial into daily practice: Outcome of palliative treatment in patients with unresectable biliary tract cancer treated with gemcitabine and cisplatin","volume":"57","author":"Dierks","year":"2018","journal-title":"Acta Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1002\/bjs.10641","article-title":"Neoadjuvant chemotherapy for initially unresectable intrahepatic cholangiocarcinoma","volume":"105","author":"Gelli","year":"2018","journal-title":"Br. J. Surg."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1016\/j.ejso.2019.03.023","article-title":"Neoadjuvant vs. adjuvant chemotherapy for cholangiocarcinoma: A propensity score matched analysis","volume":"45","author":"Yadav","year":"2019","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"EVIDoa2200015","DOI":"10.1056\/EVIDoa2200015","article-title":"Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer","volume":"1","author":"Oh","year":"2022","journal-title":"NEJM Evid."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","article-title":"Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Kelley","year":"2023","journal-title":"Lancet"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"S117","DOI":"10.1016\/j.annonc.2024.05.285","article-title":"279MO Three-year survival, safety and extended long-term survivor (eLTS) analysis from the phase III TOPAZ-1 study of durvalumab (D) plus chemotherapy in biliary tract cancer (BTC)","volume":"35","author":"Oh","year":"2024","journal-title":"Ann. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1200\/JCO.21.00679","article-title":"Modified FOLFIRINOX Versus CISGEM Chemotherapy for Patients with Advanced Biliary Tract Cancer (PRODIGE 38 AMEBICA): A Randomized Phase II Study","volume":"40","author":"Phelip","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"LBA490","DOI":"10.1200\/JCO.2023.41.4_suppl.LBA490","article-title":"SWOG 1815: A phase III randomized trial of gemcitabine, cisplatin, and nab-paclitaxel versus gemcitabine and cisplatin in newly diagnosed, advanced biliary tract cancers","volume":"41","author":"Shroff","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1001\/jamaoncol.2021.3836","article-title":"Final Overall Survival Efficacy Results of Ivosidenib for Patients with Advanced Cholangiocarcinoma with IDH1 Mutation: The Phase 3 Randomized Clinical ClarIDHy Trial","volume":"7","author":"Zhu","year":"2021","journal-title":"JAMA Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/S1470-2045(20)30157-1","article-title":"Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): A multicentre, randomised, double-blind, placebo-controlled, phase 3 study","volume":"21","author":"Macarulla","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1002\/hep.26890","article-title":"Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma","volume":"59","author":"Arai","year":"2014","journal-title":"Hepatology"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1080\/13543784.2024.2430201","article-title":"Fibroblast growth factor therapies in biliary tract cancers: Current and future state","volume":"33","author":"Siripoon","year":"2024","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMoa2206834","article-title":"Futibatinib for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma","volume":"388","author":"Goyal","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"e231476","DOI":"10.1001\/jamanetworkopen.2023.1476","article-title":"Association of BRAF Variants with Disease Characteristics, Prognosis, and Targeted Therapy Response in Intrahepatic Cholangiocarcinoma","volume":"6","author":"Xin","year":"2023","journal-title":"JAMA Netw. Open"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1016\/S1470-2045(20)30321-1","article-title":"Dabrafenib plus trametinib in patients with BRAF(V600E)-mutated biliary tract cancer (ROAR): A phase 2, open-label, single-arm, multicentre basket trial","volume":"21","author":"Subbiah","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s10555-016-9645-x","article-title":"HER2\/HER3 pathway in biliary tract malignancies; Systematic review and meta-analysis: A potential therapeutic target?","volume":"36","author":"Galdy","year":"2017","journal-title":"Cancer Metastasis. Rev."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"3207","DOI":"10.1200\/JCO.23.02010","article-title":"Trastuzumab Deruxtecan in Human Epidermal Growth Factor Receptor 2\u2013Expressing Biliary Tract Cancer (HERB; NCCH1805): A Multicenter, Single-Arm, Phase II Trial","volume":"42","author":"Ohba","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"4091","DOI":"10.1200\/JCO.2024.42.16_suppl.4091","article-title":"Zanidatamab in previously-treated HER2-positive (HER2+) biliary tract cancer (BTC): Overall survival (OS) and longer follow-up from the phase 2b HERIZON-BTC-01 study","volume":"42","author":"Pant","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1016\/S1470-2045(21)00336-3","article-title":"Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): A multicentre, open-label, phase 2a, multiple basket study","volume":"22","author":"Javle","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"113564","DOI":"10.1016\/j.ejca.2024.113564","article-title":"Revolutionizing anti-HER2 therapies for extrahepatic cholangiocarcinoma and gallbladder cancer: Current advancements and future perspectives","volume":"199","author":"Pedregal","year":"2024","journal-title":"Eur. J. Cancer"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/S0140-6736(21)00153-7","article-title":"Biliary tract cancer","volume":"397","author":"Valle","year":"2021","journal-title":"Lancet"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.aan6733","article-title":"Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade","volume":"357","author":"Le","year":"2017","journal-title":"Science"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1002\/cncr.30488","article-title":"Local therapy reduces the risk of liver failure and improves survival in patients with intrahepatic cholangiocarcinoma: A comprehensive analysis of 362 consecutive patients","volume":"123","author":"Yamashita","year":"2017","journal-title":"Cancer"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"12272","DOI":"10.1002\/cam4.5925","article-title":"Hepatic disease control in patients with intrahepatic cholangiocarcinoma correlates with overall survival","volume":"12","author":"Soares","year":"2023","journal-title":"Cancer Med."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.jhep.2023.03.010","article-title":"EASL-ILCA Clinical Practice Guidelines on the management of intrahepatic cholangiocarcinoma","volume":"79","author":"Alvaro","year":"2023","journal-title":"J. Hepatol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"694","DOI":"10.6004\/jnccn.2023.0035","article-title":"NCCN Guidelines(R) Insights: Biliary Tract Cancers, Version 2.2023","volume":"21","author":"Benson","year":"2023","journal-title":"J. Natl. Compr. Canc. Netw."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.annonc.2022.10.506","article-title":"Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Vogel","year":"2023","journal-title":"Ann. Oncol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1002\/hep.32771","article-title":"AASLD practice guidance on primary sclerosing cholangitis and cholangiocarcinoma","volume":"77","author":"Bowlus","year":"2023","journal-title":"Hepatology"},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Verma, S., Grindrod, N., Breadner, D., and Lock, M. (2024). The Current Role of Radiation in the Management of Cholangiocarcinoma-A Narrative Review. Cancers, 16.","DOI":"10.3390\/cancers16091776"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1016\/j.ijrobp.2008.03.018","article-title":"Radiation therapy is associated with improved survival in the adjuvant and definitive treatment of intrahepatic cholangiocarcinoma","volume":"72","author":"Shinohara","year":"2008","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"2975","DOI":"10.1016\/j.ejca.2014.08.013","article-title":"Gemcitabine plus cisplatin versus chemoradiotherapy in locally advanced biliary tract cancer: Federation Francophone de Cancerologie Digestive 9902 phase II randomised study","volume":"50","author":"Phelip","year":"2014","journal-title":"Eur. J. Cancer"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1200\/JCO.2015.61.3778","article-title":"Ablative Radiotherapy Doses Lead to a Substantial Prolongation of Survival in Patients with Inoperable Intrahepatic Cholangiocarcinoma: A Retrospective Dose Response Analysis","volume":"34","author":"Tao","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"8739","DOI":"10.1200\/JCO.2005.01.5354","article-title":"Phase II trial of high-dose conformal radiation therapy with concurrent hepatic artery floxuridine for unresectable intrahepatic malignancies","volume":"23","author":"Normolle","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.radonc.2018.11.015","article-title":"Stereotactic body radiotherapy dose and its impact on local control and overall survival of patients for locally advanced intrahepatic and extrahepatic cholangiocarcinoma","volume":"132","author":"Brunner","year":"2019","journal-title":"Radiother. Oncol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.prro.2021.09.004","article-title":"External Beam Radiation Therapy for Primary Liver Cancers: An ASTRO Clinical Practice Guideline","volume":"12","author":"Apisarnthanarax","year":"2022","journal-title":"Pract. Radiat. Oncol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"20180688","DOI":"10.1259\/bjr.20180688","article-title":"Stereotactic body radiation therapy in cholangiocarcinoma: A systematic review","volume":"92","author":"Frakulli","year":"2019","journal-title":"Br. J. Radiol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"4006","DOI":"10.1200\/JCO.2024.42.16_suppl.4006","article-title":"Addition of stereotactic body radiotherapy (SBRT) to systemic chemotherapy in locally advanced cholangiocarcinoma (CC) (ABC-07): Results from a randomized phase II trial","volume":"42","author":"Hawkins","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1200\/JCO.23.01402","article-title":"Elucidating the Benefit of Radiation Therapy in GI Cancers: Rethinking Trial End Points and Patient Selection","volume":"42","author":"Sanford","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1200\/JCO.2015.64.2710","article-title":"Multi-Institutional Phase II Study of High-Dose Hypofractionated Proton Beam Therapy in Patients with Localized, Unresectable Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma","volume":"34","author":"Hong","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1097\/COC.0000000000000646","article-title":"Clinical Outcomes of Patients with Unresectable Cholangiocarcinoma Treated with Proton Beam Therapy","volume":"43","author":"Hung","year":"2020","journal-title":"Am. J. Clin. Oncol."},{"key":"ref_67","first-page":"2955","article-title":"Initial Results of Hypofractionated Carbon Ion Radiotherapy for Cholangiocarcinoma","volume":"36","author":"Abe","year":"2016","journal-title":"Anticancer Res."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"4369","DOI":"10.18632\/oncotarget.27028","article-title":"Carbon-ion radiotherapy for cholangiocarcinoma: A multi-institutional study by and the Japan carbon-ion radiation oncology study group (J-CROS)","volume":"10","author":"Kasuya","year":"2019","journal-title":"Oncotarget"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"272","DOI":"10.2967\/jnumed.123.265597","article-title":"Comparison of 3 Different Therapeutic Particles in Radioembolization of Locally Advanced Intrahepatic Cholangiocarcinoma","volume":"65","author":"Wagemans","year":"2024","journal-title":"J. Nucl. Med."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1097\/PAS.0000000000001901","article-title":"Gastrointestinal Tract Injury by Yttrium-90 Appears Largely Restricted to Resin Microspheres but Can Occur Years After Embolization","volume":"46","author":"Feely","year":"2022","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1148\/radiol.2018171768","article-title":"Radiation Segmentectomy: Potential Curative Therapy for Early Hepatocellular Carcinoma","volume":"287","author":"Lewandowski","year":"2018","journal-title":"Radiology"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S2468-1253(20)30290-9","article-title":"Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): A randomised, multicentre, open-label phase 2 trial","volume":"6","author":"Garin","year":"2021","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"102258","DOI":"10.1016\/j.ctrv.2021.102258","article-title":"Locoregional therapies in patients with intrahepatic cholangiocarcinoma: A systematic review and pooled analysis","volume":"99","author":"Edeline","year":"2021","journal-title":"Cancer Treat. Rev."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/j.jceh.2022.03.008","article-title":"Unresectable Intrahepatic Cholangiocarcinoma Treated with Radiation Segmentectomy\/Lobectomy Using Yttrium 90-labeled Glass Microspheres","volume":"12","author":"Kumar","year":"2022","journal-title":"J. Clin. Exp. Hepatol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1007\/s00270-022-03183-2","article-title":"Yttrium-90 Radioembolization of Unresectable Intrahepatic Cholangiocarcinoma: Long-Term Follow-up for a 136-Patient Cohort","volume":"45","author":"Gupta","year":"2022","journal-title":"Cardiovasc. Intervent. Radiol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1007\/s00270-020-02569-4","article-title":"Yttrium-90 Radioembolization in Unresectable Intrahepatic Cholangiocarcinoma: Results of a Multicenter Retrospective Study","volume":"43","author":"Bargellini","year":"2020","journal-title":"Cardiovasc. Intervent. Radiol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/j.jvir.2020.02.008","article-title":"Yttrium-90 Radioembolization in Intrahepatic Cholangiocarcinoma: A Multicenter Retrospective Analysis","volume":"31","author":"Buettner","year":"2020","journal-title":"J. Vasc. Interv. Radiol."},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Paprottka, K.J., Galie, F., Ingrisch, M., Geith, T., Ilhan, H., Todica, A., Michl, M., Nadjiri, J., and Paprottka, P.M. (2021). Outcome and Safety after 103 Radioembolizations with Yttrium-90 Resin Microspheres in 73 Patients with Unresectable Intrahepatic Cholangiocarcinoma-An Evaluation of Predictors. Cancers, 13.","DOI":"10.3390\/cancers13215399"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1016\/j.jvir.2023.05.026","article-title":"Radioembolization with Yttrium-90 Glass Microspheres as a First-Line Treatment for Unresectable Intrahepatic Cholangiocarcinoma-A Prospective Feasibility Study","volume":"34","author":"Kis","year":"2023","journal-title":"J. Vasc. Interv. Radiol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/j.jvir.2022.10.042","article-title":"Survival and Toxicities after Yttrium-90 Transarterial Radioembolization of Cholangiocarcinoma in the RESiN Registry","volume":"34","author":"Robinson","year":"2023","journal-title":"J. Vasc. Interv. Radiol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/S1470-2045(21)00027-9","article-title":"Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): A phase 3, open-label, randomised, controlled trial","volume":"22","author":"Lamarca","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/S2468-1253(24)00119-5","article-title":"Nanoliposomal irinotecan and fluorouracil plus leucovorin versus fluorouracil plus leucovorin in patients with cholangiocarcinoma and gallbladder carcinoma previously treated with gemcitabine-based therapies (AIO NALIRICC): A multicentre, open-label, randomised, phase 2 trial","volume":"9","author":"Vogel","year":"2024","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1001\/jamaoncol.2023.0016","article-title":"Treatment with Liposomal Irinotecan Plus Fluorouracil and Leucovorin for Patients with Previously Treated Metastatic Biliary Tract Cancer: The Phase 2b NIFTY Randomized Clinical Trial","volume":"9","author":"Hyung","year":"2023","journal-title":"JAMA Oncol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1001\/jamaoncol.2019.3702","article-title":"Radioembolization Plus Chemotherapy for First-line Treatment of Locally Advanced Intrahepatic Cholangiocarcinoma: A Phase 2 Clinical Trial","volume":"6","author":"Edeline","year":"2020","journal-title":"JAMA Oncol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"4530","DOI":"10.3390\/curroncol28060384","article-title":"Selective Internal Radiation Combined with Chemotherapy Maintains the Quality of Life in Intrahepatic Cholangiocarcinomas","volume":"28","author":"Touchefeu","year":"2021","journal-title":"Curr. Oncol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1097\/HEP.0000000000000544","article-title":"Chemotherapy with or without selective internal radiation therapy for intrahepatic cholangiocarcinoma: Data from clinical trials","volume":"79","author":"Edeline","year":"2024","journal-title":"Hepatology"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/S1470-2045(15)00139-4","article-title":"Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): A randomised phase 2 trial","volume":"16","author":"Valle","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S1470-2045(14)70212-8","article-title":"Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): A randomised, open-label, non-comparative phase 2 trial","volume":"15","author":"Malka","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.18632\/oncotarget.28060","article-title":"Safety and initial efficacy of ablative radioembolization for the treatment of unresectable intrahepatic cholangiocarcinoma","volume":"12","author":"Core","year":"2021","journal-title":"Oncotarget"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"2374","DOI":"10.1007\/s00330-023-10203-3","article-title":"Selective internal radiation therapy using yttrium-90 microspheres for treatment of localized and locally advanced intrahepatic cholangiocarcinoma","volume":"34","author":"Yu","year":"2024","journal-title":"Eur. Radiol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"3729","DOI":"10.1245\/s10434-020-08486-7","article-title":"Downstaging with Radioembolization or Chemotherapy for Initially Unresectable Intrahepatic Cholangiocarcinoma","volume":"27","author":"Riby","year":"2020","journal-title":"Ann. Surg. Oncol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"3102","DOI":"10.1245\/s10434-014-4365-3","article-title":"Intra-arterial yttrium-90 radioembolization combined with systemic chemotherapy is a promising method for downstaging unresectable huge intrahepatic cholangiocarcinoma to surgical treatment","volume":"22","author":"Rayar","year":"2015","journal-title":"Ann. Surg. Oncol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1016\/j.ejrad.2016.05.020","article-title":"Comparison of Choi criteria and Response Evaluation Criteria in Solid Tumors (RECIST) for intrahepatic cholangiocarcinoma treated with glass-microspheres Yttrium-90 selective internal radiation therapy (SIRT)","volume":"85","author":"Beuzit","year":"2016","journal-title":"Eur. J. Radiol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1245\/s10434-022-12708-5","article-title":"Selective Internal Radiation Therapy (Yttrium-90 Glass Microspheres) Combined with Capecitabine in the Neoadjuvant Setting of Operable Intrahepatic CHOlangiocarcinoma: The SIROCHO Trial Design","volume":"30","author":"Edeline","year":"2023","journal-title":"Ann. Surg. Oncol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1136\/gutjnl-2017-315485","article-title":"Immune activation underlies a sustained clinical response to Yttrium-90 radioembolisation in hepatocellular carcinoma","volume":"68","author":"Chew","year":"2019","journal-title":"Gut"},{"key":"ref_96","first-page":"969","article-title":"The blood supply of neoplasms in the liver","volume":"30","author":"Breedis","year":"1954","journal-title":"Am. J. Pathol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1200\/JCO.1987.5.11.1836","article-title":"Tumor and liver drug uptake following hepatic artery and portal vein infusion","volume":"5","author":"Sigurdson","year":"1987","journal-title":"J. Clin. Oncol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1634\/theoncologist.8-6-553","article-title":"An update on hepatic arterial infusion chemotherapy for colorectal cancer","volume":"8","author":"Cohen","year":"2003","journal-title":"Oncologist"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1001\/jamaoncol.2019.3718","article-title":"Assessment of Hepatic Arterial Infusion of Floxuridine in Combination with Systemic Gemcitabine and Oxaliplatin in Patients with Unresectable Intrahepatic Cholangiocarcinoma: A Phase 2 Clinical Trial","volume":"6","author":"Cercek","year":"2020","journal-title":"JAMA Oncol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1093\/annonc\/mdp029","article-title":"Regional chemotherapy for unresectable primary liver cancer: Results of a phase II clinical trial and assessment of DCE-MRI as a biomarker of survival","volume":"20","author":"Jarnagin","year":"2009","journal-title":"Ann. Oncol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1159\/000324704","article-title":"Treating primary liver cancer with hepatic arterial infusion of floxuridine and dexamethasone: Does the addition of systemic bevacizumab improve results?","volume":"80","author":"Kemeny","year":"2011","journal-title":"Oncology"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"5528","DOI":"10.1245\/s10434-022-11439-x","article-title":"Hepatic Arterial Infusion Pump Chemotherapy for Unresectable Intrahepatic Cholangiocarcinoma: A Systematic Review and Meta-Analysis","volume":"29","author":"Holster","year":"2022","journal-title":"Ann. Surg. Oncol."},{"key":"ref_103","doi-asserted-by":"crossref","unstructured":"Cowzer, D., Soares, K., Walch, H., Gonen, M., Boucher, T.M., Do, R.K.G., Harding, J.J., Varghese, A.M., Reidy-Lagunes, D., and Saltz, L. (2024). Long term outcomes in patients with advanced intrahepatic cholangiocarcinoma treated with hepatic arterial infusion chemotherapy. J. Natl. Cancer Inst., djae202.","DOI":"10.1093\/jnci\/djae202"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jamcollsurg.2005.03.019","article-title":"Technical complications and durability of hepatic artery infusion pumps for unresectable colorectal liver metastases: An institutional experience of 544 consecutive cases","volume":"201","author":"Allen","year":"2005","journal-title":"J. Am. Coll. Surg."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1245\/s10434-024-16488-y","article-title":"Perioperative and Oncologic Outcomes of Hepatic Arterial Infusion (HAI) Pump Chemotherapy for Patients with Unresectable Colorectal Liver Metastases at an Expanding HAI Program","volume":"32","author":"Liu","year":"2024","journal-title":"Ann. Surg. Oncol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1245\/s10434-011-2102-8","article-title":"Biliary sclerosis after hepatic arterial infusion pump chemotherapy for patients with colorectal cancer liver metastasis: Incidence, clinical features, and risk factors","volume":"19","author":"Ito","year":"2012","journal-title":"Ann. Surg. Oncol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1245\/s10434-023-14488-y","article-title":"Gemcitabine with Cisplatin Versus Hepatic Arterial Infusion Pump Chemotherapy for Liver-Confined Unresectable Intrahepatic Cholangiocarcinoma","volume":"31","author":"Franssen","year":"2024","journal-title":"Ann. Surg. Oncol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1200\/JCO.2024.42.3_suppl.433","article-title":"Hepatic arterial infusion pump chemotherapy in patients with advanced intrahepatic cholangiocarcinoma confined to the liver: A multicenter phase II trial","volume":"42","author":"Franssen","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1200\/JCO.21.00608","article-title":"Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin Versus Transarterial Chemoembolization for Large Hepatocellular Carcinoma: A Randomized Phase III Trial","volume":"40","author":"Li","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jhep.2018.02.008","article-title":"Hepatic arterial infusion of oxaliplatin plus fluorouracil\/leucovorin vs. sorafenib for advanced hepatocellular carcinoma","volume":"69","author":"Lyu","year":"2018","journal-title":"J. Hepatol."},{"key":"ref_111","doi-asserted-by":"crossref","unstructured":"Yang, Z., Fu, Y., Wu, W., Hu, Z., Pan, Y., Wang, J., Chen, J., Hu, D., Zhou, Z., and Chen, M. (2023). Comparison of hepatic arterial infusion chemotherapy with mFOLFOX vs. first-line systemic chemotherapy in patients with unresectable intrahepatic cholangiocarcinoma. Front. Pharmacol., 14.","DOI":"10.3389\/fphar.2023.1234342"},{"key":"ref_112","doi-asserted-by":"crossref","unstructured":"Ishii, M., Itano, O., Morinaga, J., Shirakawa, H., and Itano, S. (2022). Potential efficacy of hepatic arterial infusion chemotherapy using gemcitabine, cisplatin, and 5-fluorouracil for intrahepatic cholangiocarcinoma. PLoS ONE, 17.","DOI":"10.1371\/journal.pone.0266707"},{"key":"ref_113","doi-asserted-by":"crossref","unstructured":"Lin, Z., Zou, X., Hu, X., Huang, D., Chen, Y., Lin, J., Li, X., and Zhang, J. (2024). Efficacy analysis of HAIC combined with lenvatinib plus PD1 inhibitor vs. first-line systemic chemotherapy for advanced intrahepatic cholangiocarcinoma. Sci. Rep., 14.","DOI":"10.1038\/s41598-024-75102-z"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1097\/00000658-198804000-00002","article-title":"Liver transplantation for malignant disease. Results in 93 consecutive patients","volume":"207","author":"Polson","year":"1988","journal-title":"Ann. Surg."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1634\/theoncologist.2-3-164","article-title":"Indications and Role of Liver Transplantation for Malignant Tumors","volume":"2","author":"Pichlmayr","year":"1997","journal-title":"Oncologist"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1002\/hep.28744","article-title":"Liver transplantation for \u201cvery early\u201d intrahepatic cholangiocarcinoma: International retrospective study supporting a prospective assessment","volume":"64","author":"Sapisochin","year":"2016","journal-title":"Hepatology"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1097\/SLA.0000000000000494","article-title":"Intrahepatic cholangiocarcinoma or mixed hepatocellular-cholangiocarcinoma in patients undergoing liver transplantation: A Spanish matched cohort multicenter study","volume":"259","author":"Sapisochin","year":"2014","journal-title":"Ann. Surg."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1111\/ajt.12591","article-title":"\u201cVery early\u201d intrahepatic cholangiocarcinoma in cirrhotic patients: Should liver transplantation be reconsidered in these patients?","volume":"14","author":"Sapisochin","year":"2014","journal-title":"Am. J. Transplant."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1002\/lt.25052","article-title":"Liver transplantation for intrahepatic cholangiocarcinoma","volume":"24","author":"Lee","year":"2018","journal-title":"Liver Transpl."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/s41575-020-0310-z","article-title":"Cholangiocarcinoma 2020: The next horizon in mechanisms and management","volume":"17","author":"Banales","year":"2020","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1002\/lt.25737","article-title":"Analysis of Liver Resection Versus Liver Transplantation on Outcome of Small Intrahepatic Cholangiocarcinoma and Combined Hepatocellular-Cholangiocarcinoma in the Setting of Cirrhosis","volume":"26","author":"Rayar","year":"2020","journal-title":"Liver Transpl."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1002\/jhbp.896","article-title":"Incidental intrahepatic cholangiocarcinoma in patients undergoing liver transplantation: A multi-center study in Japan","volume":"28","author":"Hara","year":"2021","journal-title":"J. Hepatobiliary Pancreat. Sci."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1002\/cncr.29686","article-title":"Proposal of a new staging system for intrahepatic cholangiocarcinoma: Analysis of surgical patients from a nationwide survey of the Liver Cancer Study Group of Japan","volume":"122","author":"Sakamoto","year":"2016","journal-title":"Cancer"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1111\/ajt.16906","article-title":"Survival following liver transplantation for locally advanced, unresectable intrahepatic cholangiocarcinoma","volume":"22","author":"McMillan","year":"2022","journal-title":"Am. J. Transplant."},{"key":"ref_125","doi-asserted-by":"crossref","unstructured":"Yoo, C., Jeong, H., Jeong, J.H., Kim, K.P., Lee, S., Ryoo, B.Y., Hwang, D.W., Lee, J.H., Moon, D.B., and Kim, K.H. (2024). Circulating tumor DNA status and dynamics predict recurrence in patients with resected extrahepatic cholangiocarcinoma. J. Hepatol., in press.","DOI":"10.1016\/j.jhep.2024.10.043"},{"key":"ref_126","first-page":"107","article-title":"Impact of pre-transplant immune checkpoint inhibitor use on post-transplant outcomes in HCC: A systematic review and individual patient data meta-analysis","volume":"82","author":"Yeo","year":"2024","journal-title":"J. Hepatol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/S0140-6736(24)01595-2","article-title":"Liver transplantation plus chemotherapy versus chemotherapy alone in patients with permanently unresectable colorectal liver metastases (TransMet): Results from a multicentre, open-label, prospective, randomised controlled trial","volume":"404","author":"Adam","year":"2024","journal-title":"Lancet"},{"key":"ref_128","doi-asserted-by":"crossref","unstructured":"Ahenkorah, S., Cassells, I., Deroose, C.M., Cardinaels, T., Burgoyne, A.R., Bormans, G., Ooms, M., and Cleeren, F. (2021). Bismuth-213 for Targeted Radionuclide Therapy: From Atom to Bedside. Pharmaceutics, 13.","DOI":"10.20944\/preprints202103.0699.v1"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"6148","DOI":"10.1158\/1078-0432.CCR-19-1157","article-title":"Development of a Theranostic Convergence Bioradiopharmaceutical for Immuno-PET Based Radioimmunotherapy of L1CAM in Cholangiocarcinoma Model","volume":"25","author":"Song","year":"2019","journal-title":"Clin. Cancer Res."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/32\/2\/82\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:24:51Z","timestamp":1760027091000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/32\/2\/82"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,31]]},"references-count":129,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,2]]}},"alternative-id":["curroncol32020082"],"URL":"https:\/\/doi.org\/10.3390\/curroncol32020082","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,31]]}}}